dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
Last edited 06/2023 and last reviewed 06/2023
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionNICE state:
- dapagliflozin is recommended, within its marketing authorisation, as an option for treating symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults
In the DELIVER study
- dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction (2)
- a pre-specified analysis showed that benefit of dapagliflozin was consistent across range of frailty studied & improvement in health-related quality of life with dapagliflozin occurred early and was greater in patients with greater frailty (3)
Reference:.
- NICE (June 2023). Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction
- Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022 Aug 27.
- Butt JH et al. Efficacy and Safety of Dapagliflozin According to Frailty in Patients with Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation. 2022 Aug 27
DELIVER study - dapagliflozin in heart failure with mildly reduced or preserved ejection fraction